Developing novel approaches to fight Alzheimer’s Disease
Cerebain Biotech (OTC: CBBT) is dedicated to pursuing the development and commercialization of novel treatment approaches in the fight against dementias, with a particular focus on Alzheimer’s Disease. Our vision is to apply what we know about the effect of omentum stimulation on improved cognitive function to create a new and more effective treatment paradigm. For the millions of people living with, or in fear of, an Alzheimer’s diagnosis, our success could mean hope for the future and a lifetime preserved. Our goal is the development and commercialization of a medical device with the potential to arrest or significantly slow Alzheimer’s Disease progression.
Note to investors, this site contains "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. To reference recent SEC filing information below.